Evotec’s Boardroom Exit and New T-Cell Alliance Offer Little Respite as Shares Languish Near Record Lows

The departure of a key board member and the launch of a fresh oncology partnership have done little to shift the narrative around Evotec, whose shares continue to trade perilously close to their 52-week floor. The stock last changed hands at €3.21, barely above the €3.14 low touched in early September, with the year-to-date decline now stretching to 41 percent.

Camilla Macapili Languille, who joined the supervisory board in June 2022 and served on the Audit & Compliance Committee, stepped down roughly a month ago. While the resignation has not triggered any immediate market reaction, it adds to a sense of flux enveloping the Hamburg-based biotech as it wrestles with a deteriorating earnings picture.

A Widening Gap From Peak Levels

The distance between Evotec’s current valuation and its recent highs underscores just how far sentiment has shifted. The stock reached €7.75 on November 5, 2025 — a level that now sits 58 percent above where shares trade today. That chasm reflects months of mounting operational pressure, punctuated by a profit warning in late August that shattered confidence among both institutional and retail investors.

The final first-half figures, published just over a week ago, confirmed the gloom. Second-quarter revenue contracted 16.2 percent to €143.5 million, while the full half-year saw sales fall 19.2 percent to €300.1 million. Adjusted EBITDA came in at minus €42.7 million for the period. The company had already slashed its full-year guidance in mid-July, and the numbers did nothing to alter that revised outlook: management now expects revenue of €570 million to €610 million, a marked retreat from the original €700 million to €780 million range. The adjusted EBITDA forecast has swung from a potential profit of up to €40 million to a loss of between €70 million and €105 million.

The market’s response to the confirmation was muted but telling — shares slipped 2.7 percent on the week.

New Alliance, Familiar Questions

Against this backdrop, Evotec unveiled a research collaboration with Plectonic Biotech aimed at developing T-cell-engaging therapies for solid tumors. The deal marries Evotec’s BiTco platform with Plectonic’s LOGIBODY technology, adding to a string of partnerships — including one with Odyssey Therapeutics announced in June covering autoimmune and inflammatory diseases — that the company hopes will validate its technology platforms externally.

Should investors sell immediately? Or is it worth buying Evotec?

Yet these alliances, while offering access to novel drug classes and the prospect of future milestone payments, do little to address the immediate earnings shortfall. With milestone revenues from existing partnerships already delayed, the market appears to be discounting the near-term financial impact of new deals.

Signs of Life in One Segment

Not everything in the numbers points downward. Net revenue in the Discovery, Preclinical & Translational Development (D&PD) segment climbed more than 28 percent year-over-year in the first half, which management attributes to improved client engagement and stronger commercial execution. That bright spot, however, has yet to register meaningfully in the share price, which remains well below its 50-day moving average of €3.78.

The company’s Horizon cost-reduction program is proceeding according to plan, with initial savings already banked. Management aims to cut €75 million annually by the end of 2027, targeting 20 to 30 percent of that figure in the current year alone.

A Stock Caught Between Restructuring and Reality

For investors, the calculus remains unenviable. On one side sits a company grappling with shrinking revenue and a dramatically lowered outlook; on the other, structural adjustments that may take years to bear fruit, alongside early signs of recovery in one business segment. Technical indicators offer little comfort — the relative strength index reads 38.5, hovering in neutral-to-oversold territory, while the share price trades far beneath its 200-day average of €4.95, a reminder of the entrenched downtrend.

Whether the Plectonic collaboration or the Horizon savings program can shift perceptions before further milestone delays erode confidence remains the central question. For now, the stock appears anchored near its lows, awaiting either a stabilization in the underlying numbers or concrete clinical and financial progress from one of the company’s many partnerships. The boardroom shuffle, meanwhile, leaves open the possibility of further governance changes at a company already navigating a tricky transition.